TIDMPRTC
PureTech Health PLC
25 March 2019
25 March 2019
PureTech Health plc
PureTech Health Affiliate Gelesis Presents Preclinical Data
Showing Pipeline Candidate Restores Gut Barrier Function
Treatment with developmental hydrogel prevented unwanted
substances from entering the circulation in mice with severe gut
wall injury
Data suggest Gelesis' Gel-B (GS300) repairs the seal between
intestinal epithelial cells
PureTech Health plc (LSE: PRTC) ("PureTech Health"), an advanced
biopharmaceutical company developing novel medicines for
dysfunctions of the Brain-Immune-Gut (BIG) Axis, is pleased to note
that its affiliate, Gelesis, today presented preclinical research
suggesting that pipeline candidate Gel-B (GS300) restored gut
barrier function after damage. This finding supports the potential
application of Gel-B across diseases affected by gut barrier
dysfunction, such as inflammatory bowel disease (IBD), type 2
diabetes, non-alcoholic fatty liver disease (NAFLD), and
non-alcoholic steatohepatitis (NASH). The research was presented at
ENDO 2019, the Endocrine Society's annual meeting.
Bharatt Chowrira, JD, PhD, president and chief of business &
strategy at PureTech Health, said: "Infiltration of unwanted
substances between the gut and surrounding tissues can provide a
basis for chronic inflammation. It is very encouraging to see a
novel mechanical approach for tissue repair to block such
infiltration with the potential to help treat a number of
associated diseases. It is also further proof-of-principle for the
Gelesis platform's ability to potentially deliver a range of
differentiated candidates to improve gut health and treat a host of
GI disorders beyond obesity."
The full text announcement from Gelesis is as follows:
Gelesis Presents Preclinical Data Showing Proprietary Hydrogel
Restores Gut Barrier Function
Treatment with Gelesis hydrogel prevented unwanted substances
from entering the circulation in mice with severe gut wall
injury
Data suggest Gel-B (GS300) repairs the seal between intestinal
epithelial cells
BOSTON, March 25, 2019 - Gelesis, a biotechnology company at the
forefront of developing therapies based on mechanobiology to treat
chronic diseases related to the gastrointestinal (GI) system, today
announced compelling preclinical data suggesting that the Company's
proprietary hydrogel formulation, Gel-B (GS300), restored gut
barrier function after damage. The gut barrier plays a key role in
blocking intestinal toxins from entering the circulation and
triggering disease. Building on previous preclinical work, Gel-B
was engineered to elicit the mechanical and physical properties
required to optimise intestinal tissue healing. The hydrogel, which
represents a pioneering advance in the emerging field of
mechanobiology, is being studied in diseases affected by gut
barrier dysfunction, such as inflammatory bowel disease.
The study presented at ENDO 2019, the Endocrine Society's annual
meeting, assessed the effect of Gel-B on gut barrier function in
mice following a severe insult to the gut wall by administering 3%
dextran sodium sulfate for 5 days. Mice were randomly divided into
4 doses of Gel-B (0.5%- 4.0%), control or an active Anti-p40 mAb
group. The mice treated with Gel-B had fewer epithelial barrier
breaks in distal colon samples and lower infiltration of an
ingested fluorescing agent into their circulation.
"These preclinical data support the ability of Gel-B to reverse
increased intestinal permeability in a DSS mouse model," said
Elaine Chiquette, Pharm.D., Chief Scientific Officer of Gelesis.
"We are continuing to advance our understanding of how our
proprietary hydrogel platform technology can mechanically influence
intestinal tissue repair."
Gelesis' proprietary hydrogels are made from two naturally
derived building blocks, modified cellulose cross-linked with
citric acid, that create a three-dimensional matrix.
About Gelesis
Gelesis is developing a novel hydrogel platform technology to
treat overweight and obesity and chronic diseases related to the GI
pathway. Gelesis' proprietary approach is designed to act
mechanically in the GI pathway to potentially alter the course of
chronic diseases. The company's lead product candidate, Gelesis100,
has been submitted to the FDA for review as a weight management
aid. Additionally, Gelesis is developing its second candidate,
Gelesis200, a hydrogel optimised for weight loss and glycaemic
control in patients with type 2 diabetes and prediabetes. Novel
hydrogel mechanotherapeutics based on the Gelesis platform
technology are also being advanced through a pipeline in other GI
inflammatory conditions where gut barrier and gut permeability
potentially play a role, such as non-alcoholic steatohepatitis
(NASH) and inflammatory bowel disease (IBD).
The Gelesis executive and advisory team includes some of the
world's leading experts in obesity, materials science, chronic
disease research and commercialisation. Gelesis was co-founded by
PureTech Health (LSE: PRTC), a biopharmaceutical company focused on
the Brain-Immune-Gut (BIG) axis. For more information, visit
gelesis.com or connect with us on Twitter @GelesisInc.
About PureTech Health
PureTech Health (LSE: PRTC) is an advanced biopharmaceutical
company developing BIG medicines for dysfunctions of the
Brain-Immune-Gut axis. The Company has gained deep insights into
the connection between these systems and the resulting role in
diseases that have proven resistant to established therapeutic
approaches. By harnessing this emerging field of human biology,
PureTech Health is developing new categories of medicines with the
potential to have great impact on people with serious diseases.
PureTech Health is advancing a rich pipeline of innovative
therapies with an unbiased, non-binary, and capital efficient
R&D model across its affiliates and its internal labs.
PureTech's affiliates include seven clinical-stage platforms with
two product candidates that have been filed with the US Food and
Drug Administration (FDA) for review and other novel pre-clinical
programmes. The PureTech Health pipeline includes ground-breaking
platforms and therapeutic candidates that were developed in
collaboration with some of the world's leading experts.
PureTech's internal research and development is centred on
tissue-selective immunomodulation for the treatment of oncology,
autoimmune, and CNS-related disorders, with a near-term focus on
targeting newly-discovered, foundational immunosuppressive
mechanisms in oncology and novel approaches that harness the
lymphatic infrastructure.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
Investors EU media U.S. media
Allison Mead Talbot Ben Atwell, Rob Winder Tom Donovan
+1 617 651 3156 +44 (0) 20 3727 1000 +1 857 559 3397
amt@puretechhealth.com ben.atwell@FTIconsulting.com tom@tenbridgecommunications.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAPGUPUWUPBGQA
(END) Dow Jones Newswires
March 25, 2019 14:00 ET (18:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024